Replidyne, a developer of a new class of antibiotics in collaboration with Forest Laboratories, revised the terms for its IPO on Wednesday. The Louisville, CO based company is now offering 4.5 million shares at $10. The company initially planned to offer 5 million at a range of $14-$16. Merrill Lynch and Morgan Stanley are the joint book runners for the deal.
